Pomerantz Law Firm Launches Investigation Into Beam Therapeutics Inc. for Investor Claims
Investor Alert: Pomerantz Law Firm Investigates Beam Therapeutics Inc.
Pomerantz LLP, a prominent law firm with a strong focus on corporate and securities litigation, has initiated an investigation into Beam Therapeutics Inc. (NASDAQ: BEAM) on behalf of its investors. The investigation aims to determine whether the company and certain of its officers or directors have engaged in practices that could constitute securities fraud or other unlawful activities affecting shareholders.
Context of the Investigation
This investigation comes in light of a press release issued by Beam Therapeutics on September 8, 2026, regarding new clinical data from their Phase 1/2 trial for BEAM-302, a treatment for alpha-1 antitrypsin deficiency (AATD). Beam reported that treatment with the single-dose BEAM-302 was
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.